Results 111 to 120 of about 200,281 (336)

Modulation of the Mechanisms Driving Transthyretin Amyloidosis [PDF]

, 2020
Filipa Bezerra, Maria João Saraiva, Maria Rosário Almeida   +2 more
openalex   +1 more source

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study

Circulation, 2019
Background: Hereditary transthyretin-mediated (hATTR) amyloidosis is a rapidly progressive, multisystem disease that presents with cardiomyopathy or polyneuropathy.
S. Solomon, D. Adams, A. Kristen, M. Grogan, A. González-Duarte, M. Maurer, G. Merlini, T. Damy, M. Slama, T. Brannagan, A. Dispenzieri, J. Berk, A. Shah, P. Garg, A. Vaishnaw, V. Karsten, Jihong Chen, J. Gollob, J. Vest, O. Suhr   +19 more
semanticscholar   +1 more source

JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis.

Circulation Journal, 2020
J-STAGE Advance Publication released online August 21, 2020 Mailing address: Scientific Committee of the Japanese Circulation Society, 18F Imperial Hotel Tower, 1-1-1 Uchisaiwai-cho, Chiyoda-ku, Tokyo 100-0011, Japan.
H. Kitaoka, C. Izumi, Yasuhiro Izumiya, T. Inomata, M. Ueda, T. Kubo, J. Koyama, M. Sano, Y. Sekijima, N. Tahara, N. Tsukada, K. Tsujita, H. Tsutsui, T. Tomita, M. Amano, J. Endo, A. Okada, S. Oda, S. Takashio, Yuichi Baba, Y. Misumi, M. Yazaki, T. Anzai, Y. Ando, M. Isobe, Takeshi Kimura, K. Fukuda   +26 more
semanticscholar   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Update on treatment of light chain amyloidosis

Haematologica, 2014
Light chain amyloidosis is the most common type of amyloidosis as a consequence of protein misfolding of aggregates composed of amyloid fibrils. The clinical features are dependent on the organs involved, typically cardiac, renal, hepatic, peripheral and
Shameem Mahmood, Giovanni Palladini, Vaishali Sanchorawala, Ashutosh Wechalekar   +3 more
doaj   +1 more source

Misdiagnosis of hereditary amyloidosis as AL (Primary) amyloidosis [PDF]

, 2002
Background: Hereditary, autosomal dominant amyloidosis, caused by mutations in the genes encoding transthyretin, fibrinogen A -chain, lysozyme, or apolipoprotein A-I, is thought to be extremely rare and is not routinely included in the differential ...
Booth, D.R., Booth, S.E., Bybee, A., Gilbertson, J.A., Gillmore, J.D., Hawkins, P.N., Lachmann, H.J., Pepys, M.B.   +7 more
core  

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
wiley   +1 more source

Dual-Energy SPECT and the Development of Peptide p5+14 for Imaging Amyloidosis

Molecular Imaging, 2017
Amyloidosis is associated with a number of rare diseases and is characterized by the deposition, in abdominothoracic organs and peripheral nerves, of extracellular protein fibrils, which leads to dysfunction and severe morbidity.
Jonathan S. Wall PhD, Stephen J. Kennel PhD, Emily B. Martin PhD   +2 more
doaj   +1 more source

Ursodeoxycholic acid for treatment of cholestasis in patients with hepatic amyloidosis [PDF]

, 2009
Background. Amyloidosis represents a group of different diseases characterized by extracellular accumulation of pathologic fibrillar proteins in various tissues and organs.
Akoglu Bora, Faust Dominik, Milović Vladan, Ristić Gordana   +3 more
core   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source